Conference Coverage

Are higher rifampin doses for pulmonary TB more effective?



An analysis of treatment outcomes at 12 months, a secondary endpoint, showed that there were five cases of treatment failure, including three in the control arm and one each in 15- and 20-mg/kg arms, and six cases of recurrence after cure, which occurred in three, one, and two patients, respectively,

The safety analysis by intention-to-treat showed that the incidence of grade 2 or greater rifampin-related adverse events (AEs) were 43.3%, 51.7%, and 38.3% in the 10-, 15-, and 20-mg/kg doses, differences that were not statistically significant.

In addition, there were no significant differences among the treatment arms in either time to first grade 2 or greater rifampin-related AEs, the occurrence of one or more grade 2 or greater hepatic rifampin-AEs, or time to first hepatic rifampin-related AEs of grade 2 or above.

Dr. Velásquez noted that the study was limited by the possibility that the study halts could have biased efficacy effect estimates toward null and by differences in weight distribution among the three treatment arms.


Recommended Reading

Lower C. difficile mortality with vancomycin than metronidazole
The Hospitalist
Bezlotoxumab may lower risk of C. difficile readmissions
The Hospitalist
Steroids underused in bacterial meningitis despite low risk
The Hospitalist
IGRA preferred test for latent TB diagnosis
The Hospitalist
Increasing sepsis survivorship creates new challenges
The Hospitalist
ALT-70 score outperformed thermal imaging for cellulitis diagnosis
The Hospitalist
   Comments ()